PSTX

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-2.2M ExitQ1 2025 $2M -- $9.50
Jim SimonsRenaissance Technologies $-2.6M ExitQ1 2025 $3M -- $9.50
Mario GabelliGAMCO Investors $-192.0K ExitQ1 2025 $192k -- $9.50
Ken GriffinCitadel Advisors $2.0M AddQ4 2024 $2M -- $9.50
Jim SimonsRenaissance Technologies $36.4K AddQ4 2024 $36k -- $9.50
Ken GriffinCitadel Advisors $-224.1K TrimQ3 2024 $224k -- $9.50

Insider Trades

Name	Value	Action	Price	Current Price
Gergen Mark JDirector, Officer: Executive Chairman $284k30k shares SellDec 10, 2024 $9.46 $9.50
Gergen Mark JDirector, Officer: Executive Chairman $278k30k shares SellNov 26, 2024 $9.27 $9.50

Trade PSTX

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

CEO: Mark J. Gergen
IPO Date: Jul 10, 2020

Market Data

Open: $9.58
High: $9.58
Low: $9.50
Volume: 21.3M
52W High: $9.67
52W Low: $1.87

Valuation

Market Cap: $925.9M
Enterprise Value: $966.9M

Financials

Free Cash Flow: -$95.2M
Revenue: $64.7M
Net Income: -$123.4M
Cash: $44.5M
Debt: $85.4M

Events

EarningsNov 7

EPS est. -0.41 · actual 0.21